Home › Funds › Carlyle Group Inc. › PHAT

Carlyle Group Inc. position in PHAT

PHATHOM PHARMACEUTICALS INC · Health Care

Carlyle Group Inc. reported holding 3,496,808 shares of PHAT (PHATHOM PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$25.5M, representing 0.31% of its reported portfolio and ranking #3 among its reported holdings. Carlyle Group Inc. has disclosed PHAT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)3.50M sh
Reported value held$25.53M
Portfolio Weight0.31%
First reportedQ3 2023
Last changeHold
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Carlyle Group Inc.'s PHAT position evolved

Carlyle Group Inc. first disclosed a stake in PHAT in Q3 2023 at 3,496,808 shares (US$36.2M). The position peaked in Q3 2024 at 3,496,808 shares, worth US$63.2M. Across 13 filings, Carlyle Group Inc. held the position steady without any share-count change. The most recent filing (Q3 2026) shows 3,496,808 shares valued at US$25.5M.

Quarter by quarter

QuarterSharesValueChange
Q3 2023 3.50M $36.19M New
Q4 2023 3.50M $31.93M Hold
Q1 2024 3.50M $37.10M Hold
Q2 2024 3.50M $35.84M Hold
Q3 2024 3.50M $63.19M Hold
Q4 2024 3.50M $28.39M Hold
Q1 2025 3.50M $21.92M Hold
Q2 2025 3.50M $33.53M Hold
Q3 2025 3.50M $41.05M Hold
Q4 2025 3.50M $57.98M Hold
Q1 2026 3.50M $38.85M Hold
Q2 2026 3.50M $37.94M Hold
Q3 2026 3.50M $25.53M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About PHAT and 13F data

PHAT (PHATHOM PHARMACEUTICALS INC) is a Health Care company. 29 other funds we track also report a position in PHAT — the largest reported positions include Frazier Life Sciences Management, L.P. (US$135.3M), Medicxi Ventures Management (Jersey) Ltd (US$54.5M), NEA Management Company, LLC (US$21.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding PHAT

All PHAT fund holders →

FAQ

How long has Carlyle Group Inc. held PHAT?

Carlyle Group Inc. has disclosed PHAT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Carlyle Group Inc.'s current position in PHAT?

As of Q3 2026, Carlyle Group Inc. holds 3.50M shares of PHAT (PHATHOM PHARMACEUTICALS INC), valued at $25.53M, representing 0.31% of its reported portfolio and ranking #3.

Has Carlyle Group Inc. been buying or selling PHAT?

In the latest 13F filing (Q3 2026), Carlyle Group Inc. held unchanged its position in PHAT. The position peaked in Q3 2024 at 3.50M shares.

Which other funds hold PHAT?

Other major institutional holders of PHAT include Frazier Life Sciences Management, L.P., Medicxi Ventures Management (Jersey) Ltd, NEA Management Company, LLC, among 29 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.